{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:49:32Z","timestamp":1781304572148,"version":"3.54.1"},"reference-count":42,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2014,10,26]]},"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Patients with systemic lupus erythematosus (SLE) are at higher risk of haematological malignancies (HMs) than the general population. Most reports have focused on HM diagnosed after SLE, and have excluded concurrent and preceding diagnoses. Information on response to therapy is also limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified 13\u2005296 cases of HM and 10\u2005539 potential patients with SLE at our centre; 45 patients were confirmed to have HM and SLE. Our retrospective case series was based on these 45 patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 45 patients, 64% were diagnosed with HM \u22651\u2005year <jats:italic>after<\/jats:italic> diagnosis with SLE, and 36% with HM <jats:italic>before or concurrent with<\/jats:italic> SLE. Of the 29 patients with HM after SLE, 13 had diffuse large B cell lymphoma (DLBCL), 6 indolent lymphoma, 4 leukaemia, 3 Hodgkin's disease, and 1 each Burkitt's lymphoma, T cell lymphoma and multiple myeloma. Eleven patients with DLBCL were treated with cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP) or rituximab-CHOP; hydroxydaunorubicin, oncovin and prednisone; only four achieved durable remission. Of the 16 patients diagnosed with HM before or concurrent with SLE, 9 were diagnosed with HM more than 2\u2005years before SLE and tended to be in remission prior to SLE diagnosis. Seven patients were diagnosed with HM and SLE concurrently; in terms of their HM, six achieved remission or stable disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In summary, DLBCL was the most common type of lymphoma in patients diagnosed with HM after SLE; these patients presented with advanced-stage disease and had poor outcomes. In contrast, patients diagnosed with HM before or concurrent with SLE had early stage disease and typically achieved remission.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2014-000051","type":"journal-article","created":{"date-parts":[[2014,11,15]],"date-time":"2014-11-15T01:51:32Z","timestamp":1416016292000},"page":"e000051","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Patients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapy"],"prefix":"10.1136","volume":"1","author":[{"given":"Jason S","family":"Knight","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W","family":"Blayney","sequence":"additional","affiliation":[{"name":"Stanford Cancer Center, Stanford School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C","family":"Somers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Department of Environmental Health Sciences, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,11,14]]},"reference":[{"key":"2025091513063909000_1.1.e000051.1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.38238","article-title":"Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program","volume":"66","author":"Somers","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025091513063909000_1.1.e000051.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359"},{"issue":"(5 Suppl 51)","key":"2025091513063909000_1.1.e000051.3","first-page":"S72","article-title":"An update on mortality in systemic lupus erythematosus","volume":"26","author":"Ippolito","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2025091513063909000_1.1.e000051.4","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307077987"},{"key":"2025091513063909000_1.1.e000051.5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.20.2337"},{"key":"2025091513063909000_1.1.e000051.6","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0300"},{"key":"2025091513063909000_1.1.e000051.7","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0620"},{"key":"2025091513063909000_1.1.e000051.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2008.02029.x"},{"key":"2025091513063909000_1.1.e000051.9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24141"},{"key":"2025091513063909000_1.1.e000051.10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.bor.0000209423.39033.94","article-title":"Malignancy and autoimmunity","volume":"18","author":"Bernatsky","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"2025091513063909000_1.1.e000051.11","doi-asserted-by":"publisher","DOI":"10.1191\/096120301678646128"},{"key":"2025091513063909000_1.1.e000051.12","doi-asserted-by":"publisher","DOI":"10.1080\/03009740252937568"},{"key":"2025091513063909000_1.1.e000051.13","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309102556"},{"key":"2025091513063909000_1.1.e000051.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.07.004"},{"key":"2025091513063909000_1.1.e000051.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2012.12.009"},{"key":"2025091513063909000_1.1.e000051.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.21955"},{"key":"2025091513063909000_1.1.e000051.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2243"},{"key":"2025091513063909000_1.1.e000051.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0532-7"},{"key":"2025091513063909000_1.1.e000051.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.067108"},{"key":"2025091513063909000_1.1.e000051.20","first-page":"555","article-title":"Patients with systemic lupus erythematosus (SLE) having developed malignant lymphomas. Complete remission of lymphoma following high-dose chemotherapy, but not of SLE","volume":"29","author":"Rossi","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2025091513063909000_1.1.e000051.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.069039"},{"key":"2025091513063909000_1.1.e000051.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202099"},{"key":"2025091513063909000_1.1.e000051.23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/BOR.0000000000000026","article-title":"Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies","volume":"26","author":"Bichile","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"2025091513063909000_1.1.e000051.24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000350165","article-title":"Non-lymphoma hematological malignancies in systemic lupus erythematosus","volume":"85","author":"Lu","year":"2013","journal-title":"Oncology"},{"key":"2025091513063909000_1.1.e000051.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"2025091513063909000_1.1.e000051.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"2025091513063909000_1.1.e000051.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2493"},{"key":"2025091513063909000_1.1.e000051.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0857"},{"key":"2025091513063909000_1.1.e000051.29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/art.1780170407","article-title":"Malignancy in a series of 70 patients with systemic lupus erythematosus","volume":"17","author":"Canoso","year":"1974","journal-title":"Arthritis Rheum"},{"key":"2025091513063909000_1.1.e000051.30","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0140-6736(78)92645-4","article-title":"Systemic lupus erythematosus and lymphoma","volume":"2","author":"Green","year":"1978","journal-title":"Lancet"},{"key":"2025091513063909000_1.1.e000051.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390625"},{"key":"2025091513063909000_1.1.e000051.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400424"},{"key":"2025091513063909000_1.1.e000051.33","doi-asserted-by":"publisher","DOI":"10.1191\/096120301678416079"},{"key":"2025091513063909000_1.1.e000051.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.51.4.437"},{"key":"2025091513063909000_1.1.e000051.35","first-page":"217","article-title":"Increased risk of malignancy in patients with systemic lupus erythematosus","volume":"46","author":"Ramsey-Goldman","year":"1998","journal-title":"J Investig Med"},{"key":"2025091513063909000_1.1.e000051.36","first-page":"1478","article-title":"Risk of malignancy in women with systemic lupus erythematosus","volume":"22","author":"Sweeney","year":"1995","journal-title":"J Rheumatol"},{"key":"2025091513063909000_1.1.e000051.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.21029"},{"key":"2025091513063909000_1.1.e000051.38","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.034504"},{"key":"2025091513063909000_1.1.e000051.39","first-page":"7","article-title":"Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and Non-Hodgkin's lymphoma: a single center experience","volume":"99","author":"Altintas","year":"2008","journal-title":"Minerva Med"},{"key":"2025091513063909000_1.1.e000051.40","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04587.x"},{"key":"2025091513063909000_1.1.e000051.41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-008-9069-8","article-title":"Spontaneous remission of \u201cmethotrexate-associated lymphoproliferative disorders\u201d after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature","volume":"26","author":"Rizzi","year":"2009","journal-title":"Med Oncol"},{"key":"2025091513063909000_1.1.e000051.42","doi-asserted-by":"publisher","DOI":"10.1002\/art.21674"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2014-000051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:06:48Z","timestamp":1757966808000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2014-000051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,11,14]]},"published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1136\/lupus-2014-000051"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2014-000051","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}